Fortress Biotech (FBIO)
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emr...
- Open
- 2.800
- High
- 2.875
- Low
- 2.794
- Prev. Close
- 2.770
- Volume
- 202.72K
- Turnover
- 575.76K
- Avg Price
- 2.840
- Bid/Ask Ratio
- --
- Amplitude
- 2.92%
- 52wk High
- 4.530
- Volume Ratio
- 0.41
- Turnover Ratio
- 0.87%
Fortress Biotech Analyst Rating
View moreForecast & Rating
May 18, 2026Price forecast
$11.00283.28%
Forecast & RatingStrong buy
2analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · Aug 13 at 06:56 PM
Fortress Biotech (NASDAQ:FBIO) Posts Earnings Results, Beats Estimates By $0.12 EPS
- PUBT · Aug 13 at 03:07 PM
Fortress Biotech Q2 FY26 turns to net loss of $2.5 million; revenue rises 14% to $18.7 million
- Market Beat · Aug 12 at 06:04 PM
Fortress Biotech Q2 Earnings Call Highlights
- Quartr · Aug 12 at 03:39 PM
FBIO: Q1 2026 net income soared to $108.4M, fueled by PRV sale and ZYCUBOⓇ approval
- prnewswire · Aug 7 at 11:45 AM
12:45 ETSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Fortress Biotech, Inc. (NASDAQ: FBIO)
- PUBT · Jul 27 at 07:05 AM
Fortress Biotech subsidiary Urica says Crystalys closes $130 million Series B financing
